Beam Therapeutics filed litigation alleging a former scientist stole confidential information and used it to co-found a Chinese company tied to a competing gene-editing program. Beam alleges that Zi Jun “Emma” Wang accessed Beam electronic lab notebooks and used the information to help create YolTech Therapeutics, later connected to Serapha Bio through a licensing arrangement. The lawsuit frames the dispute as an IP and trade secret theft case amid rising US-China biotech tensions, where investors and sponsors have increasingly focused on the risk of copied technologies and rival programs. For the industry, the dispute is a reminder that beyond scientific performance, the defensibility of editing platforms and proprietary know-how remains a critical factor for long-term value creation.